TUMOR BIOLOGICAL MARKERS AS THE BASIS FOR PERSONALIZED MEDICINE IN ONCOLOGY

DOI: https://doi.org/None

E.S. Gershtein N.N. Blokhin Russian Cancer Research Center, Kashirskoe shosse, 24, Moscow, Russian Federation, 115478

The key role in the achievement of the main goals of personalized medicine in oncology i.e. treatment choice according to patient’s individual characteristics and biological properties of the tumor belongs to tumor molecular markers characterizing the specificity of biological behavior of tumor cell and such fundamental properties of malignant tumors as invasion, metastasizing, unlimited proliferation, resistance to apoptosis, neoangiogenic activity, and sensitivity to exogenous and endogenous regulators. In this lecture, the main biologically significant human tumor molecular markers (steroid hormone receptors, growth factors, their receptors and downstream signaling proteins, tumor-associated proteases, angiogenic markers) and their role in therapy decision making and prognosis of its results are reviewed. Methodical aspects, achievements of pre-clinical studies, requirements for inclusion of a marker to the clinical practice, and international recommendations on clinical implications of these parameters are discussed. The recent data on the possibilities and pitfalls of the usage of modern high throughput technologies (microarrays, real-time PCR-arrays, DNA sequencing) as an alternative to the determination of individual molecular markers are analyzed
Keywords: 
tumor biological markers, steroid hormone receptors, growth factors, growth factor receptors, protein kinases, tumorassociated proteases, angiogenic markers, somatic mutations
Список литературы: 
  1. Duffy M.J. Evidence for the clinical use of tumour markers. Ann. Clin. Biochem. 2004; 41 (Pt. 5): 370–7.
  2. Duffy M.J. Predictive markers in breast and other cancers: a review. Clin. Chemistry. 2005; 51 (3): 494–503.
  3. Modjtahedi H., Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs. 2009, 20 (10): 851–5.
  4. Antonicelli A., Cafarotti S., Indini A. et al. EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation. Int. J. Med. Sci. 2013; 10 (3): 320–30.
  5. Okada Y., Miyamoto H., Goji T. et al. Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer. Digestion. 2014; 89 (1): 18–23.
  6. Brunelli M., Manfrin E., Martignoni G. et al. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy. Am. J. Clin. Pathol. 2008; 129 (6): 907–11.
  7. Pusztai L., Mazouni C., Anderson K. et al. Molecular classification of breast cancer: limitations and potential. Oncologist. 2006; 11 (8): 868–77.
  8. Gershtein E.S., Scherbakov A.M., Shatskaya V.A., Kushlinsky N.E., Krasil’nikov M.A. Phosphatidylinositol 3-kinase/AKT signalling pathway components in human breast cancer: clinicopathological correlations. Anticancer Res. 2007; 27 (4A): 1777–82.
  9. Zhou Y., Eppenberger-Castori S., Eppenberger U., Benz C.C. The NFkappaB pathway and endocrine-resistant breast cancer. Endocr. Relat. Cancer. 2005; 12 (Suppl. 1): 37–46.
  10. O’Reilly T., McSheehy P.M. Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes. Limitations and Further Proposals. Transl. Oncol. 2010; 3 (2): 65–79.
  11. Look M.P., van Putten W.L.J., Duffy M.J. et al. Pooled analysis of prognostic impact of tumor biological factors uPA and PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst. 2002; 94 (2): 116–28.
  12. Persing M.M., Paepke D., Schmidt M. et al. on behalf of the NNBC-3 Study Group. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 for improved management in node-negative (N0) breast cancer: Experiences from the ongoing multicenter trial NNBC 3-Europe. J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2007; 25: N18S (June 20 Supplement). 11081.
  13. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003; 9 (6): 669–76.
  14. Marchionni L., Wilson R.F., Wolff A.C. et al. Systematic review: gene expression profiling assays in early-stage breast cancer. Ann. Intern. Med. 2008; 148 (5): 358–69.
  15. Ross J.S., Hatzis C., Symmans W.F. et al. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist. 2008; 13 (5): 477–93.
  16. Maak M., Simon I., Nitsche U. et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann. Surg. 2013; 257 (6): 1053